Inhibition of DNA restriction enzyme digestion by anthracyclines.
The inhibition of restriction enzyme digestion of lambda phage DNA by anthracyclines (i.e., adriamycin, daunomycin, epirubicin, idarubicin and esorubicin) commonly used in the treatment of human leukemia and cancer has been studied in vitro. The anthracyclines used inhibit DNA digestion by SmaI, AvaII, HaeIII, HhaI and HpaII, which cut DNA at guanine-cytosine (G-C) sequence sites, and by EcoRI, which cut DNA at adenine adenine-thymine thymine (AATT) sequence sites. Adriamycin completely inhibits DNA restriction by the indicated enzymes, daunomycin, epirubicin and idarubicin determine only a partial inhibition, while esorubicin does not inhibit DNA restriction at all. An attempt is made to correlate the extent of the in vitro interaction between anthracyclines and DNA to in vivo cardiotoxicity.
Corneo
G
G
Cattedra di Patologia Medica II, Università degli Studi di Milano.
Pogliani
E
E
Biassoni
D
D
Tripputi
P
P
D000903:Antibiotics, Antineoplastic; D010582:Bacteriophage lambda / Q000187:drug effects / Q000378:metabolism; D004262:DNA Restriction Enzymes / Q000037:antagonists & inhibitors*; D004279:DNA, Viral / Q000378:metabolism; D009279:Naphthacenes / Q000378:metabolism / Q000494:pharmacology
D000903:Antibiotics, Antineoplastic; D004279:DNA, Viral; D009279:Naphthacenes; D004262:DNA Restriction Enzymes